epiq scripts tirzepatide https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound Home

Therapeutic Considerations BPC-157 is more stable than its parent compound, and studies indicate that it does not require a carrier agent to elicit systemic effects

However, the weight loss and improved insulin sensitivity from Mounjaro can help stabilise your overall metabolic health, which may indirectly improve hormonal balance particularly if you had insulin resistance or PCOS-related hormonal issues

VZV also targets CD8+ T cells

Extensive research supports tighter glucose control to reduce complications

The SURMOUNT-1 trial showed tirzepatide 15 mg weekly produced 22% average weight loss over 72 weeks, significantly exceeding single-pathway GLP-1 agents

Individual results range from 5% to 22% depending on baseline weight, genetics, medication adherence, and lifestyle changes